Another panel (including AABs against survivin, p53, p16, cyclin B1, cyclin D1, cyclin A, cyclin E, Koc, IGF2 mRNA-binding protein 1 (IMP1), P62, cyclin-dependent kinase 2 (CDK2), P90, and c-MYC) achieved a sensitivity of 62.5% and a specificity of 85% in the detection of ovarian cancer [104]. This evidence concerns the gene CDK2 and ovarian cancer.